Farms.com Home   News

G3 Swift Current Loads First Train On Loop Track

The newest grain terminal in the South West loaded its first train on a loop track yesterday.

Farmers started delivering grain to the G3 Swift Current terminal in Mid-May.

G3 Corporate Communication Specialist Peter Chura said in an earlier interview that the Swift Current facility is similar to other G3 operations.

"It has a capacity of 42,000 tonnes. It has high capacity drags and the drive shed, meaning a 40 ton Super B truck could discharge its whole load of grain there within five minutes or less and be back on its way back to the farm for another load."

He notes on the other side of the facility is the loop track.

"This means a 150 car train could pull onto the loop track, continue moving around, continuous motion, it gets loaded and gets on its way to in this case G3 Terminal Vancouver. It keeps the grain moving, keeps the grain moving to market, which means more delivery opportunities, and more market opportunities for farmers."

The grain company now has 17 elevators across the Prairies, nine in Saskatchewan and six in Alberta

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.